YYFZBJS inhibits colorectal tumorigenesis by enhancing Tregs-induced immunosuppression through HIF-1α mediated hypoxia in vivo and in vitro
- PMID: 35093671
- DOI: 10.1016/j.phymed.2021.153917
YYFZBJS inhibits colorectal tumorigenesis by enhancing Tregs-induced immunosuppression through HIF-1α mediated hypoxia in vivo and in vitro
Abstract
Background and purpose: The occurrence of colorectal cancer (CRC) is associated with a variety of factors. Accumulating evidence shows that peripheral differentiation of regulatory T cells (Tregs) is critical in controlling tumorigenesis. Our previous studies demonstrated that the Yi-Yi-Fu-Zi-Bai-Jiang-San (YYFZBJS) extract exerted potent anticancer activities by significantly enhancing immunosuppression in ApcMin/+ mice. However, there is limited knowledge on the effect of YYFZBJS in the prevention of colorectal cancer and the underlying mechanisms of action.
Methods: In this study, we investigated the effect of oral administration of YYFZBJS in preventing azoxymethane (AOM)/dextran sulfate sodium (DSS)-induced tumorigenesis. We found that YYFZBJS treatment decreased tumor load, tumor number, histology, and the severity of disease activity index (DAI) scores. To investigate if YYFZBJS inhibited tumorigenesis by regulating regulatory T cells, we depleted Tregs in AOM/DSS mice. We then analyzed the effect of intragastric administration of YYFZBJS on tumorigenesis and the regulation of tumor microenvironment.
Results: As expected, intragastric administration of YYFZBJS in AOM/DSS mice model significantly increased immune responses in the tumor microenvironment through its hypoxia-associated anti-cancer activities. Additionally, YYFZBJS regulated the polarization of peripheral Treg (pTreg) to suppress CRC cell proliferation and infiltration. This was demonstrated by the decrease in tumor proliferation-related proteins including p-STAT3, p-NF-κB and MMPs in a dose-dependent manner. Clinically, the increase in the levels of Tregs in human tissues during CRC progression was associated with low expression of HIF-1α in the stroma, and correlated with CRC survival and prognosis.
Conclusion: Altogether, we demonstrated that HIF-1α may promote pTreg -induced carcinogenesis and progression of CRC cells, indicating that YYFZBJS is a promising protective agent against HIF-1α-mediated Treg activation in colorectal cancer. This study is the first to imply a novel clinical significance of a traditional Chinese herbal medicine from Synopsis of Golden Chamber in the cancer treatment and clarify the important role of tumor microenvironment in preventing tumorigenesis.
Keywords: AOM/DSS-induced colitis-associated colorectal cancer; Colorectal cancer; HIF-1α; Traditional Chinese herb medicine; Tregs.
Copyright © 2022 The Author(s). Published by Elsevier GmbH.. All rights reserved.
Similar articles
-
YYFZBJS inhibits colorectal tumorigenesis by remodeling gut microbiota and influence on M2 macrophage polarization in vivo and in vitro.Am J Cancer Res. 2021 Nov 15;11(11):5338-5357. eCollection 2021. Am J Cancer Res. 2021. PMID: 34873464 Free PMC article.
-
YYFZBJS ameliorates colorectal cancer progression in ApcMin/+ mice by remodeling gut microbiota and inhibiting regulatory T-cell generation.Cell Commun Signal. 2020 Jul 16;18(1):113. doi: 10.1186/s12964-020-00596-9. Cell Commun Signal. 2020. PMID: 32677955 Free PMC article.
-
Exploring the potential mechanisms of Yi-Yi-Fu-Zi-Bai-Jiang-San therapy on the immune-inflamed phenotype of colorectal cancer via combined network pharmacology and bioinformatics analyses.Comput Biol Med. 2023 Nov;166:107432. doi: 10.1016/j.compbiomed.2023.107432. Epub 2023 Aug 30. Comput Biol Med. 2023. PMID: 37729701
-
Integrated network pharmacology and experimental verification to investigate the mechanisms of YYFZBJS against colorectal cancer via CDK1/PI3K/Akt signaling.Front Oncol. 2022 Nov 15;12:961653. doi: 10.3389/fonc.2022.961653. eCollection 2022. Front Oncol. 2022. PMID: 36457504 Free PMC article.
-
The Interplay of Autophagy and Tumor Microenvironment in Colorectal Cancer-Ways of Enhancing Immunotherapy Action.Cancers (Basel). 2019 Apr 14;11(4):533. doi: 10.3390/cancers11040533. Cancers (Basel). 2019. PMID: 31013961 Free PMC article. Review.
Cited by
-
Enhancing cancer immunotherapy: Nanotechnology-mediated immunotherapy overcoming immunosuppression.Acta Pharm Sin B. 2024 Sep;14(9):3834-3854. doi: 10.1016/j.apsb.2024.05.032. Epub 2024 Jun 3. Acta Pharm Sin B. 2024. PMID: 39309502 Free PMC article. Review.
-
Potential Effects of Traditional Chinese Medicine in Anti-Aging and Aging-Related Diseases: Current Evidence and Perspectives.Clin Interv Aging. 2024 May 1;19:681-693. doi: 10.2147/CIA.S447514. eCollection 2024. Clin Interv Aging. 2024. PMID: 38706635 Free PMC article. Review.
-
YTE-17 inhibits colonic carcinogenesis by resetting antitumor immune response via Wnt5a/JNK mediated metabolic signaling.J Pharm Anal. 2024 Apr;14(4):100901. doi: 10.1016/j.jpha.2023.11.008. Epub 2023 Nov 29. J Pharm Anal. 2024. PMID: 38665223 Free PMC article.
-
Murine models of colorectal cancer: the azoxymethane (AOM)/dextran sulfate sodium (DSS) model of colitis-associated cancer.PeerJ. 2023 Oct 31;11:e16159. doi: 10.7717/peerj.16159. eCollection 2023. PeerJ. 2023. PMID: 37927787 Free PMC article. Review.
-
Advances in research on the effectiveness and mechanism of Traditional Chinese Medicine formulas for colitis-associated colorectal cancer.Front Pharmacol. 2023 Feb 23;14:1120672. doi: 10.3389/fphar.2023.1120672. eCollection 2023. Front Pharmacol. 2023. PMID: 36909166 Free PMC article. Review.
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous